PTCL, NOS: An update on classification, risk-stratification, and treatment

The peripheral T-cell lymphomas (PTCL) are relatively rare, heterogeneous, and therapeutically challenging. While significant therapeutic gains and improved understanding of disease pathogenesis have been realized for selected PTCL subtypes, the most common PTCL in North America remains "not ot...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 13; p. 1101441
Main Authors Weiss, Jonathan, Reneau, John, Wilcox, Ryan A
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 09.02.2023
Subjects
classification
GATA-3
Oncology
PTCL
PTCL-NOS
risk stratification
treatment
PTCL-NOS
PTCL
treatment
risk stratification
classification
GATA-3
Online AccessGet full text

Cover

More Information
Summary:The peripheral T-cell lymphomas (PTCL) are relatively rare, heterogeneous, and therapeutically challenging. While significant therapeutic gains and improved understanding of disease pathogenesis have been realized for selected PTCL subtypes, the most common PTCL in North America remains "not otherwise specified (NOS)" and is an unmet need. However, improved understanding of the genetic landscape and ontogeny for the PTCL subtypes currently classified as PTCL, NOS have been realized, and have significant therapeutic implications, which will be reviewed here.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Reviewed by: Reuben Matthew Tooze, University of Leeds, United Kingdom; Anjali Mishra, Sidney Kimmel Cancer Center, United States; Brad Haverkos, University of Colorado Hospital, United States
Edited by: Jean El Cheikh, American University of Beirut Medical Center, Lebanon
This article was submitted to Hematologic Malignancies, a section of the journal Frontiers in Oncology
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2023.1101441